CompletedPhase 2NCT04091490

Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)

Studying Classic Hodgkin lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Principal Investigator
Vladislav Sarzhevskiy, PhD
National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation
Intervention
Nivolumab(drug)
Enrollment
40 enrolled
Eligibility
18-65 years · All sexes
Timeline
20202022

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04091490 on ClinicalTrials.gov

Other trials for Classic Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Classic Hodgkin lymphoma

← Back to all trials